Epigenetic rewiring of pathways related to odour perception in immune cells exposed to SARS-CoV-2 in vivo and in vitroArticle Published on 2022-12-012023-07-09 Journal: Epigenetics [Category] COVID19(2023년), [키워드] DNA methylation in vitro stimulation interactome Mild-to-moderate module identification network analysis. PBMC SARS-CoV-2 [DOI] 10.1080/15592294.2022.2089471 PMC 바로가기
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial재조합 인터페론 무장 융합 단백질 백신(V-01)을 사용한 SARS-CoV-2에 대한 이종 부스팅의 효능: 무작위, 이중 맹검 및 위약 대조 3상 시험Clinical Trial Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] adverse event antibody assigned booster clinical trial common adverse event conducted COVID-19 vaccine COVID-19 vaccines dose double-blind dramatic increase Efficacy elicit eligible fatigue Fever fusion protein groups headache healthy Heterologous heterologous boosting Humoral immunity Identifier Immunity inactivated Inactivated vaccine Inactivated Vaccines Inc injection injection site intention-to-treat principle Malaysia Mild-to-moderate Neutralizing Neutralizing antibodies occurred Older omicron Omicron variant over Pain participant Participants Placebo placebo-controlled primary endpoint Randomized Randomly receive regimen robust Safe SARS-CoV-2 SARS-COV-2 infection second dose Serious Adverse Events subunit Subunit vaccine Subunit vaccine. Surveillance symptomatic SARS-CoV-2 infection the epidemic titre Trial Trial registration V-01 Vaccine vaccine efficacy variant virus-neutralizing antibodies was measured were assessed [DOI] 10.1080/22221751.2022.2088406 PMC 바로가기 [Article Type] Clinical Trial
Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomesArticle Published on 2022-11-122022-11-15 Journal: Biochemical and Biophysical Research Communication [Category] SARS, 변종, 치료제, [키워드] acute respiratory syndrome Adaptability Antiviral approved circulating coronavirus correlation COVID-19 cases COVID-19 pandemic develop drug resistance FDA highest hotspot intracellular protein Like M pro main protease Mild-to-moderate mutant Mutation mutations Nirmatrelvir offer omicron predicted Probability protease Protein design reported residue residues resistance resistance mutations robust SARS-CoV-2 SARS-CoV-2 lineage signature Signatures of adaptation. Surveillance unique variant Variation variations viral adaptation viral genome viruses [DOI] 10.1016/j.bbrc.2022.09.010 PMC 바로가기
Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in QatarArticle Published on 2022-11-012022-11-15 Journal: International Journal of Infectious Diseases [Category] SARS, 진단, [키워드] 95% confidence interval adjusted odds ratio Analysis BA.2 case-control study conducted Control control group controls COVID-19 COVID-19 severity Critical Disease progression drug Effectiveness eligible Epidemiology Evidence fatal COVID-19 food form high-risk patient higher risk incidence individual Mild-to-moderate neutralizing antibody occurred omicron Patient progression protective effect receive reducing SARS-CoV-2 Sotrovimab Sotrovimab. study period Subgroup analysis subgroup of patient Treatment treatment group United State [DOI] 10.1016/j.ijid.2022.09.023 PMC 바로가기
Bamlanivimab Use in a Military Treatment FacilityArticle Published on 2022-10-292022-11-15 Journal: Military Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome Administered administration Admission analyzed approval approved Arm bamlanivimab Care caused cohort study coronavirus coronavirus disease COVID-19 COVID-19 patient death declined diagnosed Disease progression facility FDA Follow-up Guidance help hospital Hospital admission Hospitalization information initial inpatient admission institutional review board intravenous IRB lack Mild-to-moderate monoclonal antibody Patient patients patients with SARS-CoV-2 placebo group Prevent Primary outcome progression provided receiving replicated reported required retrospective risk risk factor SARS-CoV-2 secondary outcome self-reported symptom severe COVID-19 small sample size Spread statistical significance statistically significant Study design Symptom treated Treatment treatment group virus-neutralizing was obtained were given Wuhan, China [DOI] 10.1093/milmed/usab188 PMC 바로가기
Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 – United States, January-July 2022Article Published on 2022-10-282022-11-15 Journal: Morbidity and Mortality Weekly Report [Category] 치료제, [키워드] African American Alaska Antiviral Antiviral treatment antivirals Asian black booster doses Care COVID-19 COVID-19 in patient COVID-19 patient COVID-19 treatments COVID-19 vaccination disparity drug EHR Emergency use authorization EUA facilitate food Health help high risk highest Hispanic patient Immunocompromised less mAb medication Mild-to-moderate molnupiravir monoclonal antibody Native outcomes Outpatient Patient patient groups patients Paxlovid PROTECT Racial Remdesivir report risk seeking severe COVID-19 treated Treatment United States were used White patients [DOI] 10.15585/mmwr.mm7143a2 PMC 바로가기
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a PartArticle Published on 2022-10-182022-11-15 Journal: Antimicrobial Agents and Chemotherapy [Category] COVID19(2023년), SARS, 치료제, [키워드] acute respiratory syndrome All adverse event Asymptomatic baseline clinical coronavirus coronavirus disease COVID-19 Culture demonstrated double-blind Efficacy and safety ensitrelvir fumaric acid greater group groups intention-to-treat population Japan Japanese log median time Mild Mild-to-moderate moderate multicenter novel oral Part Patient phase phase 2/3 Placebo positive Primary outcome proof-of-concept study protease Protease inhibitor Randomized receive reduced registry Result S-217622 SARS-CoV-2 SARS-CoV-2 3C-like protease inhibitor SARS-CoV-2 clearance SARS-COV-2 infection SARS-CoV-2 RNA SARS-CoV-2 viral the SARS-CoV-2 tissue Treatment viral clearance Viral RNA viral titer viral titer. [DOI] 10.1128/aac.00697-22 PMC 바로가기
Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for useArticle Published on 2022-10-012022-11-15 Journal: European Journal of Clinical Pharmacology [Category] COVID19(2023년), SARS, 신약개발, 치료제, [키워드] absence antidepressant antidepressants antiviral drug approved article benefit Care Clinical outcome clinical trial coronavirus COVID COVID-19 database death decrease drug effort Hospitalization Infection infections information inhibit inhibitor Intensive intubation methodological flaws Mild-to-moderate mortality rates Novel coronavirus pandemic patients receptor Redirection reduce reported repositioning Repositioning. Research risk SARS-CoV-2 SciELO selective Serotonin shown specific treatment therapeutic intervention Toxicity treat Treatment viral titer was performed [DOI] 10.1007/s00228-022-03372-5 PMC 바로가기
Coronavirus disease 2019 (COVID-19)-related smell and taste impairment with widespread diffusion of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) Omicron variantArticle Published on 2022-10-012022-11-16 Journal: International forum of allergy & rhinology [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI 95% confidence interval Characteristics chemosensory clinical presentation coronavirus disease Coronavirus disease 2019 COVID-19 diffusion dropped dysfunction evaluated impairment Infection Mild-to-moderate olfactory olfactory dysfunction omicron Omicron variant outcomes Patient patients positive Prevalence Prospective reported SARS-CoV-2 sense of smell sense of taste severity significantly significantly lower Smell study cohort subject taste dysfunction Taste. variant widespread [DOI] 10.1002/alr.22995 PMC 바로가기
Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severityArticle Published on 2022-09-272022-11-15 Journal: Frontiers in Immunology [Category] 진단, [키워드] accompanied ADRA2A ADRB2 alteration analyzed Asymptomatic autoantibodies autoantibody autonomic Autonomic nervous system autonomous chronic chronic fatigue syndrome classification Classifier Control control group control groups correlated correlation COVID COVID-19 Diagnostic Criteria disease dysregulation Evidence exploratory study fatigue G-protein G-protein coupled receptor groups immunoregulation indicated involved ME/CFS, Mild-to-moderate MOST nervous system organ dysfunction outcomes Pathogenesis Patient patients plethora Post COVID syndrome random receptor receptors Regulatory renin-angiotensin system renin-angiotensin system. seronegative serum severity STAB1 subset Symptom symptom severity syndrome [DOI] 10.3389/fimmu.2022.981532 PMC 바로가기